Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00945906 · ClinicalTrials.gov registry record · Phase 3
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Phase 3 study of Factor XIII Deficiency, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT00945906 is a Phase 3 study of Factor XIII Deficiency that has completed, run by CSL Behring. The registered enrollment target is 61 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT00945906, a Phase 3 study of Factor XIII Deficiency, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
Congenital deficiency of factor XIII is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII. Factor XIII Concentrate works by assisting blood in the usual clotting process, thereby preventing bleeding. In this study, patients will be treated with FXIII Concentrate (Human) and followed closely to determine that they receive the dose of FXIII Concentrate (Human) that will best minimize the chance of bruising and bleeding. The purpose of the study is to provide FXIII Concentrate (Human) to patients until the product becomes commercially available in the United States.
Conditions Studied
Interventions
- BIOLOGICAL FXIII Concentrate (Human) (FXIII)
Study Locations (20)
California
- Study Site - Oakland
- Study Site - Orange
- Study Site - San Francisco
- Study Site - Stockton
Florida
- Study Site - Fort Myers
- Study Site - Miami
- Study Site - St. Petersburg
Michigan
- Study Site - Ann Arbor
- Study Site - Detroit
New York
- Study Site - Albany
- Study Site - New York
Alabama
- Study Site - Dothan
Louisiana
- Study Site - New Orleans
Massachusetts
- Study Site - Boston
Missouri
- Study Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00945906
The ClinicalTrials.gov registry entry for NCT00945906 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Factor XIII Deficiency appearing as the primary indexed condition, and to 1 intervention - of which FXIII Concentrate (Human) (FXIII) is the first listed.
NCT00945906 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT00945906 about?
NCT00945906 is a clinical study titled "An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency". Congenital deficiency of factor XIII is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII. Factor XIII Concentrate works by assisting blood in the usual clotting process, thereby...
What is the current status of trial NCT00945906?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2009-09. Estimated completion is 2011-08.
What conditions does trial NCT00945906 study?
This clinical trial studies the following conditions: Factor XIII Deficiency.
What interventions are being tested in trial NCT00945906?
The interventions under investigation include: FXIII Concentrate (Human) (FXIII) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00945906?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00945906 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Factor XIII Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.